Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 26, Issue 1, Pages 187-197Publisher
IOS PRESS
DOI: 10.3233/JAD-2011-110080
Keywords
Alzheimer's disease; gene expression; histone acetylation; histone deacetylases; memory impairment
Categories
Funding
- EURYI
- ERA-Net Neuron Project Epitherapy
- Hans and Ilse Breuer Foundation
- German Research Foundation (DFG) [SA/1050/2-1]
- EMBO
Ask authors/readers for more resources
Dysregulation of histone acetylation has been implicated in the onset of age-associated memory impairment and the pathogenesis of neurodegenerative diseases. Elevation of histone acetylation via administration of histone deacetylase (HDAC) inhibitors is currently being pursued as a novel therapeutic avenue to treat memory impairment linked to Alzheimer's disease (AD). Here we show that severe amyloid pathology correlates with a pronounced dysregulation of histone acetylation in the forebrain of APPPS1-21 mice. Importantly, prolonged treatment with the pan-HDAC inhibitor sodium butyrate improved associative memory in APPPS1-21 mice even when administered at a very advanced stage of pathology. The recovery of memory function correlated with elevated hippocampal histone acetylation and increased expression of genes implicated in associative learning. These data advance our understanding of the potential applicability of HDAC inhibitors for the treatment of AD and suggest that HDAC inhibitors may have beneficial effects even when administered long after the onset of disease-associated symptoms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available